RET in breast cancer: Functional and therapeutic implications

Trends in Molecular Medicine

Volumn 17, Issue 3, 2011, Pages 149-157

  Morandi, Andrea ^a   Plaza Menacho, Ivan ^b   Isacke, Clare M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ARTEMIN; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; EXEMESTANE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FULVESTRANT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GOSERELIN; IMATINIB; LETROZOLE; LEUPRORELIN; MESSENGER RNA; MOTESANIB; NEURTURIN; PACLITAXEL; PERSEPHIN; PROTEIN BCL 2; PROTEIN RET; RILOTUMUMAB; SORAFENIB; SUNITINIB; TAMOXIFEN; TRELSTA; TRIPTORELIN; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; XL 184;

BILE DUCT CARCINOMA; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESTROGEN RESPONSIVE ELEMENT; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HORMONAL THERAPY; HUMAN; LOSS OF FUNCTION MUTATION; LUNG CANCER; MISSENSE MUTATION; NONHUMAN; PANCREAS CANCER; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THYROID CARCINOMA; TRANSCRIPTION INITIATION;

ANIMALS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-RET;

EID: 79952444251     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2010.12.007     Document Type: Review

References (87)

1. EBCTCG Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351:1451-1467.
2. Buzdar A.U. Aromatase inhibitors: changing the face of endocrine therapy for breast cancer. Breast Dis. 2005, 24:107-117.
3. Osborne C.K., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 2002, 20:3386-3395.
4. Johnston S.R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010, 16:1979-1987.
5. Cleator S.J., et al. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin. Breast Cancer 2009, 9(Suppl. 1):S6-S17.
6. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
7. Musgrove E.A., Sutherland R.L. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 2009, 9:631-643.
8. Airaksinen M.S., Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 2002, 3:383-394.
9. Ichihara M., et al. RET and neuroendocrine tumors. Cancer Lett. 2004, 204:197-211.
10. Arighi E., et al. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev. 2005, 16:441-467.
11. Drosten M., Putzer B.M. Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy. Nat. Clin. Pract. Oncol. 2006, 3:564-574.
12. Plaza-Menacho I., et al. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet. 2006, 22:627-636.
13. Imkamp F., et al. Rearrangement analysis in archival thyroid tissues: punching microdissection and artificial RET/PTC 1-12 transcripts. J. Surg. Res. 2007, 143:350-363.
14. Nakashima M., et al. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum. Pathol. 2007, 38:621-628.
15. Cebrian A., et al. Polymorphisms in the initiators of RET (rearranged during transfection) signaling pathway and susceptibility to sporadic medullary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2005, 90:6268-6274.
16. Robledo M., et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res. 2003, 63:1814-1817.
17. Sawai H., et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res. 2005, 65:11536-11544.
18. Narita N., et al. Functional RET G691S polymorphism in cutaneous malignant melanoma. Oncogene 2009, 28:3058-3068.
19. Dawson D.M., et al. Altered expression of RET proto-oncogene product in prostatic intraepithelial neoplasia and prostate cancer. J. Natl. Cancer Inst. 1998, 90:519-523.
20. Ito Y., et al. Expression of glial cell line-derived neurotrophic factor family members and their receptors in pancreatic cancers. Surgery 2005, 138:788-794.
21. Zeng Q., et al. The relationship between overexpression of glial cell-derived neurotrophic factor and its RET receptor with progression and prognosis of human pancreatic cancer. J. Int. Med. Res. 2008, 36:656-664.
22. Takaya K., et al. Expression of the RET proto-oncogene in normal human tissues, pheochromocytomas, and other tumors of neural crest origin. J. Mol. Med. 1996, 74:617-621.
23. Iwahashi N., et al. Expression of glial cell line-derived neurotrophic factor correlates with perineural invasion of bile duct carcinoma. Cancer 2002, 94:167-174.
24. Ohshima Y., et al. c-RET molecule in malignant melanoma from oncogenic RET-carrying transgenic mice and human cell lines. PLoS One 2010, 5:e10279.
25. Kan Z., et al. Diverse somatic mutation patterns and pathway alterations in human cancers. Nature 2010, 466:869-873.
26. Portella G., et al. Development of mammary and cutaneous gland tumors in transgenic mice carrying the RET/PTC1 oncogene. Oncogene 1996, 13:2021-2026.
27. Kawai K., et al. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation. Cancer Res. 2000, 60:5254-5260.
28. Okada Y., et al. Experimental implication of celiac ganglionotropic invasion of pancreatic-cancer cells bearing c-ret proto-oncogene with reference to glial-cell-line-derived neurotrophic factor (GDNF). Int. J. Cancer 1999, 81:67-73.
29. Tang J.Z., et al. Artemin-stimulated progression of human non-small cell lung carcinoma is mediated by BCL2. Mol. Cancer Ther. 2010, 9:1697-1708.
30. Pandey V., et al. Artemin stimulates oncogenicity and invasiveness of human endometrial carcinoma cells. Endocrinology 2010, 151:909-920.
31. Garnis C., et al. Chromosome 5p aberrations are early events in lung cancer: implication of glial cell line-derived neurotrophic factor in disease progression. Oncogene 2005, 24:4806-4812.
32. Qiao S., et al. Increased expression of glial cell line-derived neurotrophic factor and neurturin in a case of colon adenocarcinoma associated with diffuse ganglioneuromatosis. Clin. Neuropathol. 2009, 28:105-112.
33. Frisk T., et al. Expression of RET and its ligand complexes, GDNF/GFRalpha-1 and NTN/GFRalpha-2, in medullary thyroid carcinomas. Eur. J. Endocrinol. 2000, 142:643-649.
34. Lindahl M., et al. Human glial cell line-derived neurotrophic factor receptor alpha 4 is the receptor for persephin and is predominantly expressed in normal and malignant thyroid medullary cells. J. Biol. Chem. 2001, 276:9344-9351.
35. Esseghir S., et al. A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer. Cancer Res. 2007, 67:11732-11741.
36. Plaza-Menacho I., et al. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance. Oncogene 2010, 29:4648-4657.
37. Boulay A., et al. The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer. Cancer Res. 2008, 68:3743-3751.
38. Tozlu S., et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr. Relat. Cancer 2006, 13:1109-1120.
39. Unger K., et al. Novel gene rearrangements in transformed breast cells identified by high-resolution breakpoint analysis of chromosomal aberrations. Endocr. Relat. Cancer 2010, 17:87-98.
40. Lee H., et al. MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells. Mol. Endocrinol. 2000, 14:1882-1896.
41. Arpino G., et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr. Rev. 2008, 29:217-233.
42. Arpino G., et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J. Natl. Cancer Inst. 2007, 99:694-705.
43. Fagan D.H., Yee D. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J. Mammary Gland Biol. Neoplasia 2008, 13:423-429.
44. Martin L.A., et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr. Relat. Cancer 2005, 12:1017-1036.
45. Turner N., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010, 70:2085-2094.
46. Kang J., et al. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma. Oncogene 2010, 29:3228-3240.
47. Burmi, R.S. et al. (2006) Microarray studies reveal novelgenes associated with endocrine resistance in breast cancer. Breast Cancer Res. 8, Suppl 2, S11.
48. Hutcheson I.R., et al. Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy. Endocr. Relat. Cancer 2006, 13(Suppl. 1):S89-S97.
49. Kuno R., et al. The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes. Brain Res. 2006, 1116:12-18.
50. Appel E., et al. Regulation of GDNF expression in cultured astrocytes by inflammatory stimuli. Neuroreport 1997, 8:3309-3312.
51. de Visser K.E., et al. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006, 6:24-37.
52. Ben-Baruch A. The multifaceted roles of chemokines in malignancy. Cancer Met. Rev. 2006, 25:357-371.
53. Zuercher W.J., et al. Current review of small molecule Ret kinase inhibitors. Mini Rev. Med. Chem. 2010, 10:138-146.
54. Akeno-Stuart N., et al. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells. Cancer Res. 2007, 67:6956-6964.
55. Licitra L., et al. Multikinase inhibitors in thyroid cancer. Eur. J. Cancer 2010, 46:1012-1018.
56. Phay J.E., Shah M.H. Targeting RET receptor tyrosine kinase activation in cancer. Clin. Cancer Res. 2010, 16:5936-5941.
57. Modi S., et al. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res. Treat. 2005, 90:157-163.
58. Cristofanilli M., et al. Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. Ann. Oncol. 2008, 19:1713-1719.
59. Yardley D.A., et al. Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer. Clin. Breast Cancer 2009, 9:237-242.
60. Chow L.W., et al. Evaluation of neoadjuvant inhibition of aromatase activity and signal transduction in breast cancer. Cancer Lett. 2008, 262:232-238.
61. Coxon A., et al. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors. Clin. Cancer Res. 2009, 15:110-118.
62. Rosen P.J., et al. A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors. Clin. Cancer Res. 2010, 16:2677-2687.
63. de Boer, R. et al. (2009) Primary analysis of a phase 1b combination study of Motesanib (AMG 706) with paclitaxel or docetaxel for the treatment of locally recurrent, unresectable or metastatic breast cancer. Cancer Res. 69, Supplement 3, Abstract 205.
64. Moreno-Aspitia A., et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J. Clin. Oncol. 2009, 27:11-15.
65. Isaacs C., et al. Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer. Breast Cancer Res. Treat. 2011, 125:137-143.
66. Murray L.J., et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin. Exp. Metastasis 2003, 20:757-766.
67. Burstein H.J., et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J. Clin. Oncol. 2008, 26:1810-1816.
68. Barrios C.H., et al. Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Res. Treat. 2010, 121:121-131.
69. Kozloff M., et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann. Oncol. 2010, 21:1436-1441.
70. Miller K.D., et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin. Cancer Res. 2005, 11:3369-3376.
71. Herbst R.S., et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010, 11:619-626.
72. Rosen L.S., et al. Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 2010, 15:216-235.
73. deGraffenried L.A., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. Clin. Cancer Res. 2004, 10:8059-8067.
74. DeGraffenried L.A., et al. Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 2004, 15:1510-1516.
75. Schermuly R.T., et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Invest. 2005, 115:2811-2821.
76. de Groot J.W., et al. Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia Type 2A and 2B associated RET mutations. Surgery 2006, 139:806-814.
77. Polverino A., et al. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. 2006, 66:8715-8721.
78. Caenepeel S., et al. Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J. Exp. Clin. Cancer Res. 2010, 29:96.
79. Wilhelm S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
80. Carlomagno F., et al. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006, 98:326-334.
81. Plaza-Menacho I., et al. Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J. Biol. Chem. 2007, 282:29230-29240.
82. Kim D.W., et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J. Clin. Endocrinol. Metab. 2006, 91:4070-4076.
83. Karaman M.W., et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 2008, 26:127-132.
84. Wedge S.R., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res. 2002, 62:4645-4655.
85. Wells S.A., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 2010, 28:767-772.
86. Herbst R.S., et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin. Investig. Drugs 2007, 16:239-249.
87. Cui J. Inhibitors targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Expert Opin. Ther. Pat. 2006, 16:713-718.